Loading
Finerenone / Heart Failure / Acute Heart Failure · Phase 3 Trial
ClinicalTrials.gov · September 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 3 randomized controlled trial registry record comparing finerenone to placebo in hospitalized patients with acute decompensated heart failure and mildly reduced or preserved ejection fraction. No results have been posted; the study is actively recruiting with primary outcomes (composite HF events and CV death, serious adverse events, and discontinuations) ongoing for up to approximately 30 months.
Phase 3, Interventional, Randomized, Parallel, Quadruple masking, Treatment purpose. Heart Failure, Acute Heart Failure; age from 18 Years. Intervention: Finerenone. Compared with: Placebo — Placebo Comparator. n = 5,200. 356 sites across 26 countries.
This is a Phase 3 randomized controlled trial registry record comparing finerenone to placebo in hospitalized patients with acute decompensated heart failure and mildly reduced or preserved ejection fraction. No results have been posted; the study is actively recruiting with primary outcomes (composite HF events and CV death, serious adverse events, and discontinuations) ongoing for up to approximately 30 months.
No effect sizes, confidence intervals, p-values, or safety data are available.
The source did not state who this applies to in practice.
This is a clinical trial registry record describing a planned Phase 3 study with no results reported; the study is actively recruiting and outcomes remain ongoing.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06008197). This is a study registration, not published results. Lead sponsor: Colorado Prevention Center. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 5200 participants (ESTIMATED). Conditions: Heart Failure, Acute Heart Failure. Interventions: DRUG: Finerenone; DRUG: Placebo. Primary outcome measures: Composite of total HF events and cardiovascular (CV) death. , Ongoing, up to ~30 months; Number of serious adverse events. , Ongoing, up to ~30 months; Number of adverse events leading to discontinuation of study drug. , Ongoing, up to ~30 months. Brief summary: Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.